‘Be ready against cancer, now’: direct-to-consumer advertising for genetic testing

Abstract A recent addition to the debate about the benefits and harms of direct-to-consumer (DTC) advertising of medicines and pharmaceuticals is a growing critique of DTC marketing and sale of genetic tests. Academic and policy literatures exploring this issue have, however, tended to focus on the sale of genetic tests, paying rather less attention to the particular implications of advertising. The globalization of broadcast media and ever increasing access to the Internet mean that public exposure to advertising for medical technologies is a reality that national regulatory bodies will be hard pressed to constrain. Working through a case study detailing Myriad Genetics' 2002 pilot advertising campaign for their BRACAnalysis genetic susceptibility test for hereditary breast and ovarian cancer, this paper highlights some of the diverse and often overlooked and unregulated approaches to DTC advertising, and the associated social, ethical and policy implications.

[1]  T. Caulfield,et al.  Genetic testing, ethical concerns, and the role of patent law , 2000, Clinical genetics.

[2]  G. Zinkhan,et al.  Trust in Online Prescription Drug Information Among Internet Users , 2003, Health marketing quarterly.

[3]  W. DeJong,et al.  A Content Analysis of Direct-to-Consumer Television Prescription Drug Advertisements , 2004, Journal of health communication.

[4]  Joel Lexchin,et al.  Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[5]  N. Holtzman.  Are Genetic Tests Adequately Regulated? , 1999, Science.

[6]  A. Alman,et al.  Use of the Internet by patients and their families to obtain genetics-related information. , 2001, Mayo Clinic proceedings.

[7]  S. Wolfe.  Direct-to-consumer advertising--education or emotion promotion? , 2002, The New England journal of medicine.

[8]  R. Pinkus.  From Lydia Pinkham to Bob Dole: What the Changing Face of Direct-to-Consumer Drug Advertising Reveals about the Professionalism of Medicine , 2002, Kennedy Institute of Ethics journal.

[9]  J. Lexchin,et al.  Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No , 2002 .

[10]  Nhs Confederation.  Our inheritance, our future: realising the potential of genetics in the NHS (DOH White Paper) , 2003 .

[11]  S. Hutson.  Attitudes and psychological impact of genetic testing, genetic counseling, and breast cancer risk assessment among women at increased risk. , 2003, Oncology nursing forum.

[12]  J. Huh,et al.  Is the Information “Fair and Balanced” in Direct-to-Consumer Prescription Drug Websites? , 2004, Journal of health communication.

[13]  Gail Geller,et al.  Mapping the human genome: An assessment of media coverage and public reaction , 2002, Genetics in Medicine.

[14]  Olufunmilayo I Olopade,et al.  Direct-to-consumer marketing of genetic tests for cancer: buyer beware. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Moynihan,et al.  On music , 2002, BMJ : British Medical Journal.

[16]  C. Isaacs,et al.  BRCA1/2 testing: complex themes in result interpretation. , 2001, Journal of Clinical Oncology.

[17]  Michael M. Burgess,et al.  Providing Genetic Testing Through the Private Sector: A View From Canada , 2001 .

[18]  S B Soumerai,et al.  Coverage by the news media of the benefits and risks of medications. , 2000, The New England journal of medicine.

[19]  Sara Chandros Hull,et al.  Limitations of direct-to-consumer advertising for clinical genetic testing. , 2002, JAMA.

[20]  Andrew Herxheimer,et al.  Relationships between the pharmaceutical industry and patients' organisations , 2003, BMJ : British Medical Journal.

[21]  J. Gerberding,et al.  Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. , 2004, MMWR. Morbidity and mortality weekly report.

[22]  M. Cho,et al.  Guidelines for advertising on health web sites: who's guarding the Koop. , 2000, The Western journal of medicine.

[23]  H. Cuckle,et al.  Direct marketing of cystic fibrosis carrier screening: commercial push or population need? , 1995, Journal of Medical Genetics.

[24]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[25]  B. Wilfond,et al.  Direct-to-consumer sales of genetic services on the Internet , 2003, Genetics in Medicine.

[26]  P. Rubin.  Pharmaceutical advertising as a consumer empowerment device. , 2001, The journal of biolaw & business.

[27]  S. Findlay.  Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers. , 2001, PharmacoEconomics.

[28]  R. Carter,et al.  BRCA1, BRCA2 and breast cancer: a concise clinical review. , 2001, Clinical and investigative medicine. Medecine clinique et experimentale.

[29]  R. Hoedemaekers.  Commercial predictive testing: the desirability of one overseeing body , 2000, Journal of medical ethics.

[30]  M. Fisher.  Physicians and the Pharmaceutical Industry: A Dysfunctional Relationship , 2003, Perspectives in biology and medicine.

[31]  B. Ponder,et al.  Familial predisposition to breast cancer in a British population: implications for prevention. , 2000, European journal of cancer.

[32]  R. Eeles,et al.  Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information , 2003, Journal of medical ethics.

[33]  D. Melzer,et al.  Genetics and medicalisation , 2002, BMJ : British Medical Journal.

[34]  M. Burgess.  Marketing and Fear Mongering , 1999 .

[35]  S. Coney.  Direct-to-Consumer Advertising of Prescription Pharmaceuticals: A Consumer Perspective from New Zealand , 2002 .

[36]  S. Seal,et al.  BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. King,et al.  Population genetics of BRCA1 and BRCA2. , 1997, American journal of human genetics.

[39]  E. Berndt,et al.  Promotion of prescription drugs to consumers. , 2002, The New England journal of medicine.

[40]  Philip Gendall,et al.  Direct-to-Consumer Advertising down Under: An Alternative Perspective and Regulatory Framework , 2002 .

[41]  W. Rubinstein,et al.  Prophylactic mastectomy: obstacles and benefits. , 2001, Journal of the National Cancer Institute.

[42]  Joel J. Davis.  Riskier Than We Think? The Relationship Between Risk Statement Completeness and Perceptions of Direct to Consumer Advertised Prescription Drugs , 2000, Journal of health communication.

[43]  T. Sellers,et al.  Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. , 2001, Journal of the National Cancer Institute.

[44]  S. Narod.  Modifiers of risk of hereditary breast and ovarian cancer , 2002, Nature Reviews Cancer.

[45]  Michael Dean,et al.  CCR2 chemokine receptor and AIDS progression , 1997, Nature Medicine.

[46]  Trevor Jackson.  Regulator spells out rules on disease awareness campaigns , 2003, British medical journal.

[47]  B. Williams-Jones,et al.  Social Contract Theory and Just Decision Making: Lessons from Genetic Testing for the BRCA Mutations , 2004, Kennedy Institute of Ethics journal.

[48]  S. Hull,et al.  Reading between the lines: direct-to-consumer advertising of genetic testing. , 2001, The Hastings Center report.

[49]  R. Kravitz,et al.  Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey , 2002, BMJ : British Medical Journal.

[50]  Bryn Williams-Jones,et al.  Where There’s a Web, There’s a Way: Commercial Genetic Testing and the Internet , 2003, Public Health Genomics.

[51]  L. Lerer.  Pharmaceutical Marketing Segmentation in the Age of the Internet , 2002 .

[52]  Roxanne Mykitiuk,et al.  Caveat Emptor: Direct-to-Consumer Supply and Advertising of Genetic Testing , 2004, Clinical and investigative medicine. Medecine clinique et experimentale.

[53]  B. Williams-Jones.  History of a gene patent: tracing the development and application of commercial BRCA testing. , 2002, Health law journal.

[54]  S. Hull,et al.  Reading between the lines: Direct-to-consumer advertising of genetic testing in the USA , 2001, Reproductive health matters.

[55]  G. Zinkhan,et al.  Direct-to-Consumer Advertising and its Utility in Health Care Decision Making: A Consumer Perspective , 2004, Journal of health communication.